Literature DB >> 27364574

Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.

R Nedaeinia1,2, M Sharifi3, A Avan4, M Kazemi3, L Rafiee5, M Ghayour-Mobarhan4,6, R Salehi3.   

Abstract

Colorectal cancer (CRC) is the third leading cause of cancer-related death and has an extremely poor prognosis. Dysregulation of microRNAs (miRNAs) has been shown to be involved in the pathogenesis and progression of many malignancies. Recent data suggest that microRNA-21 (miR-21) is significantly elevated in different types of cancer, especially colon adenocarcinoma. Against this background, locked nucleic acid (LNA)-modified oligonucleotides have recently been suggested as a novel approach for targeting miRNAs as antisense-based gene silencing. The aim of the current study was to explore the functional role of LNA-anti-miR-21 in a colon adenocarcinoma LS174T cell line. LS174T cells were transfected with LNA-anti-miR-21 for 24, 48 and 72 h. Quantitative real-time reverse transcriptase-PCR (qRT-PCR) was performed to assess miR-21 expression by LNA-anti-miR-21. The viability of the cells was evaluated by MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) assay and Annexin V/propidium iodide staining assay was used to detect apoptosis. Moreover, invasive behavior of the cells was evaluated before and after therapy by transwell assay. LNA-anti-miR-21 was successfully transfected in human LS174T cells and suppressed the endogenous miR-21. LNA-anti-miR-21 inhibited the cells' growth followed by induction of apoptosis. LNA-anti-miR-21 (50 pmol/μl) reduced the invasive behaviors of LS174T cells after 24 h, compared with untreated cells and scrambled LNA-transfected cells. However, this effect was more pronounced after 72 h. Our findings suggest the therapeutic potential of LNA-anti-miR-21 in a colon adenocarcinoma for targeting miR-21 expression. Further studies are warranted to investigate the molecular mechanisms underlying this novel inhibitor in colorectal cancer to establish its potential value for treatment of CRC patients with high miR-21 expression.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27364574     DOI: 10.1038/cgt.2016.25

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  46 in total

Review 1.  MicroRNAs: key players in carcinogenesis and novel therapeutic targets.

Authors:  A H F Mirnezami; K Pickard; L Zhang; J N Primrose; G Packham
Journal:  Eur J Surg Oncol       Date:  2008-07-21       Impact factor: 4.424

2.  Blockage of miR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia.

Authors:  M Sharifi; R Salehi
Journal:  Cancer Gene Ther       Date:  2015-12-11       Impact factor: 5.987

Review 3.  The road toward microRNA therapeutics.

Authors:  Anita G Seto
Journal:  Int J Biochem Cell Biol       Date:  2010-03-19       Impact factor: 5.085

4.  Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens.

Authors:  Yingjie Yu; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

5.  Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.

Authors:  Hajime Shibuya; Hisae Iinuma; Ryu Shimada; Atsushi Horiuchi; Toshiaki Watanabe
Journal:  Oncology       Date:  2011-03-17       Impact factor: 2.935

Review 6.  Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

Authors:  Kim Y C Fung; Edouard Nice; Ilka Priebe; Damien Belobrajdic; Aloke Phatak; Leanne Purins; Bruce Tabor; Celine Pompeia; Trevor Lockett; Timothy E Adams; Antony Burgess; Leah Cosgrove
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

7.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

8.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

9.  Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.

Authors:  O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula
Journal:  Oncology       Date:  2008-01-15       Impact factor: 2.935

Review 10.  MicroRNAs: novel regulators in the hallmarks of human cancer.

Authors:  Kai Ruan; Xiaoguang Fang; Gaoliang Ouyang
Journal:  Cancer Lett       Date:  2009-05-22       Impact factor: 8.679

View more
  21 in total

Review 1.  Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Deepak Narayanan Iyer; Lui Ng
Journal:  Histol Histopathol       Date:  2019-10-16       Impact factor: 2.303

2.  Suppression of STAT3 NH2 -terminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via de-repression by microRNA-21.

Authors:  Sutapa Ray; Don W Coulter; Shawn D Gray; Jason A Sughroue; Shrabasti Roychoudhury; Erin M McIntyre; Nagendra K Chaturvedi; Kishor K Bhakat; Shantaram S Joshi; Timothy R McGuire; John G Sharp
Journal:  Mol Carcinog       Date:  2018-01-25       Impact factor: 4.784

3.  Simultaneous Targeting of Multiple oncomiRs with Phosphorothioate or PNA-Based Anti-miRs in Lymphoma Cell Lines.

Authors:  Karishma Dhuri; Sai Pallavi Pradeep; Jason Shi; Eleni Anastasiadou; Frank J Slack; Anisha Gupta; Xiao-Bo Zhong; Raman Bahal
Journal:  Pharm Res       Date:  2022-09-07       Impact factor: 4.580

Review 4.  MicroRNAs regulating Wnt signaling pathway in colorectal cancer: biological implications and clinical potentials.

Authors:  Faeze Ahmadi Beni; Mohammad Kazemi; Hassan Dianat-Moghadam; Mohadeseh Behjati
Journal:  Funct Integr Genomics       Date:  2022-10-20       Impact factor: 3.674

Review 5.  An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Authors:  Justine M Grixti; Duncan Ayers; Philip J R Day
Journal:  Noncoding RNA       Date:  2021-04-16

6.  Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment.

Authors:  Peiyuan Zhang; Xiaohui Liu; Daniel Abegg; Toru Tanaka; Yuquan Tong; Raphael I Benhamou; Jared Baisden; Gogce Crynen; Samantha M Meyer; Michael D Cameron; Arnab K Chatterjee; Alexander Adibekian; Jessica L Childs-Disney; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2021-08-13       Impact factor: 16.383

Review 7.  From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?

Authors:  Mostafa Vaghari-Tabari; Niloufar Targhazeh; Soheila Moein; Durdi Qujeq; Forough Alemi; Maryam Majidina; Simin Younesi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

Review 8.  Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.

Authors:  Dinh-Duc Nguyen; Suhwan Chang
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

Review 9.  The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; Bimal Kumar Sarkar; Sang-Soo Lee
Journal:  Oncotarget       Date:  2018-01-23

Review 10.  Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates.

Authors:  Santiago Grijalvo; Adele Alagia; Andreia F Jorge; Ramon Eritja
Journal:  Genes (Basel)       Date:  2018-02-06       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.